Skip to main content

Table 3 Metastasis:Liver SUVmax ratio 12 Stable patients

From: Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression

Patient

Met 1

R1

R2

Met 2

R1

R2

Met 3

R1

R2

Met 4

R1

R2

Met 5

R1

R2

1

Node

2.72

3.51

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

2

Lung

3.29

1.93

Node

0.93

1.36

Node

1.44

1.30

NA

NA

NA

NA

NA

NA

3

Node

1.67

0.84

Bone

1.42

0.96

NA

NA

NA

NA

NA

NA

NA

NA

NA

4

Liver

2.62

4.04

Liver

1.57

2.12

Bowel

1.53

2.11

Peritoneal

1.43

2.77

Bowel

1.06

1.18

5

Bowel

2.39

2.76

Bowel

1.22

1.29

Node

0.90

1.01

Bone

0.76

0.78

NA

NA

NA

6

Bone

0.76

1.08

Bone

1.05

0.54

Saliv Gland

2.28

2.06

Bone

0.92

0.85

Bone

4.60

3.73

7

Bone

2.26

3.48

Bone

2.62

4.04

Bowel

1.58

4.36

Bone

1.47

4.37

Liver

2.47

3.18

8

Liver

1.73

3.83

Liver

1.61

4.89

Liver

1.38

2.44

Liver

1.18

2.63

Bone

0.72

1.43

9

Bowel

0.72

1.29

Liver

2.16

2.57

Bone

1.58

2.40

Bone

3.44

4.28

NA

NA

NA

10

Node

2.20

5.70

Bone

1.76

4.83

Bone

0.83

2.39

Node

1.51

4.32

Bone

2.20

7.80

11

Bowel

1.71

1.52

Bowel

2.64

3.05

Node

3.22

3.69

Bowel

2.78

2.68

Node

3.10

3.93

12

Liver

1.43

3.71

Bowel

0.96

2.06

Bowel

1.30

2.35

Bowel

1.05

1.84

Bowel

2.91

5.13

  1. Met 1–5 = Location of metastasis, R1 = Baseline Metastasis:Liver SUVmax ratio R2 = Post SSA Metastasis:Liver Uptake ratio